This is a paid press release. Contact the press release distributor directly with any enquiries.
Chiesi Global <a href="https://healthylife7.com/opinion-early-access-to-all-drugs-for-rare-diseases-is-pie-in-sky-unless-we-tax-to-fund-it/” title=”Opinion: Early access to all drugs for rare diseases is pie in sky unless we tax to fund it”>Rare Diseases Demonstrates Its Ongoing Commitment to the Rare Disease Community at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium
Chiesi Global Rare Diseases
Fri, 28 August 2026 at 12:30 pm GMT+5:30
12 min read
— Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes inFabry disease and alpha-mannosidosis —
— Rooted in patient voice and scientific rigor, this research reflects Chiesi’s long-standing role in advancing science for thelysosomal storage disorderscommunity —
PARMA, Italy, Aug. 28, 2026 (GLOBE NEWSWIRE) — Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced presentations at the Society of Inborn Errors of Metabolism (SSIEM) 2026 Annual Symposium, held August 25-28, 2026, in Helsinki, Finland. The company is proud to support 13 scientific abstracts across Fabry disease and alpha-mannosidosis, including 6 Chiesi-led presentations and 7 independent studies supported by Chiesi through scientific research grants and educational projects. These abstracts reflect the scope of the Company’s scientific engagement with the lysosomal storage disorders (LSDs) and rare disease communities.
These abstracts highlight the breadth of research advancing the understanding of Fabry disease and alpha-mannosidosis. Chiesi-led presentations include long-term Phase 3 data from the F60/BRILLIANCE trial, patient-reported outcomes from a cross-sectional survey in untreated Fabry disease, and research exploring earlier diagnosis and genotype–phenotype relationships in alpha-mannosidosis. Independent studies supported by Chiesi examine real-world clinical experience, disease biology, biomarkers and newborn screening. Together, this research contributes to a growing body of evidence to advance understanding of disease burden, diagnosis and long-term management in rare diseases.
“Rare disease care demands patience, precision, and an unwavering focus on the people we’re ultimately trying to help. The data presented at this year’s SSIEM Annual Symposium reflects years of collaboration with investigators, clinicians, and the Fabry disease and alpha-mannosidosis communities,” said Enrico Piccinini, Senior Vice President, Europe and International, Chiesi Global Rare Diseases. “From new tools that could help identify diagnosis earlier to long-term data on treatment outcomes, this research is united by a single goal: better understanding the experiences of people living with rare diseases and using those insights to help inform care. We’re proud to have shared these findings with the broader scientific community and remain devoted to advancing solutions that make a meaningful difference.”
